Ovid Therapeutics to Host Investor Event
Ovid Therapeutics (Nasdaq: OVID) has announced an investor event called KCC2 Download Day scheduled for November 13, 2024, from 9:30 to 11:30 am ET at their New York headquarters. The event will focus on their portfolio of direct potassium chloride co-transporter 2 (KCC2) activators, including updates on OV350, their lead program.
Three distinguished speakers will present: Dr. Jeffrey Noebels from Baylor College of Medicine, Dr. Karl Kieburtz from University of Rochester School of Medicine, and Dr. Stephen Moss from Tufts University. The event will be available via webcast, and in-person attendees can register through Ovid's Investor Relations.
Ovid Therapeutics (Nasdaq: OVID) ha annunciato un evento per investitori chiamato KCC2 Download Day, previsto per il 13 novembre 2024, dalle 9:30 alle 11:30 ET, presso la loro sede a New York. L'evento si concentrerà sul loro portafoglio di attivatori diretti del co-trasportatore di cloruro di potassio 2 (KCC2), inclusi aggiornamenti su OV350, il loro programma principale.
Tre relatori distinti presenteranno: Dr. Jeffrey Noebels del Baylor College of Medicine, Dr. Karl Kieburtz della University of Rochester School of Medicine, e Dr. Stephen Moss della Tufts University. L'evento sarà disponibile tramite webcast e i partecipanti in presenza possono registrarsi attraverso le Relazioni con gli Investitori di Ovid.
Ovid Therapeutics (Nasdaq: OVID) ha anunciado un evento para inversores llamado KCC2 Download Day programado para el 13 de noviembre de 2024, de 9:30 a 11:30 am ET en su sede de Nueva York. El evento se centrará en su cartera de activadores directos del co-transportador de cloruro de potasio 2 (KCC2), incluidas actualizaciones sobre OV350, su programa principal.
Tres oradores distinguidos presentarán: Dr. Jeffrey Noebels del Baylor College of Medicine, Dr. Karl Kieburtz de la University of Rochester School of Medicine, y Dr. Stephen Moss de la Tufts University. El evento estará disponible a través de webcast, y los asistentes presenciales pueden registrarse a través de las Relaciones con Inversores de Ovid.
Ovid Therapeutics (Nasdaq: OVID)는 2024년 11월 13일 오전 9시 30분부터 11시 30분까지 뉴욕 본사에서 KCC2 다운로드 데이라는 투자자 행사를 발표했습니다. 이 행사는 그들의 직접적인 칼륨 클로라이드 공수송체 2(KCC2) 활성제 포트폴리오와 OV350이라는 주요 프로그램에 대한 업데이트에 초점을 맞춥니다.
세 명의 저명한 연사가 발표할 예정입니다: Dr. Jeffrey Noebels (베일러 의과대학), Dr. Karl Kieburtz (로체스터 대학교 의과대학) 및 Dr. Stephen Moss (타프츠 대학교). 이 행사는 웹캐스트로 제공되며, 현장 참석자는 Ovid의 투자자 관계를 통해 등록할 수 있습니다.
Ovid Therapeutics (Nasdaq: OVID) a annoncé un événement pour les investisseurs intitulé KCC2 Download Day prévu le 13 novembre 2024, de 9h30 à 11h30 HE dans leur siège à New York. L'événement se concentrera sur leur portefeuille d'activateurs directs du co-transporteur de chlorure de potassium 2 (KCC2), avec des mises à jour sur OV350, leur programme phare.
Trois intervenants éminents présenteront : Dr. Jeffrey Noebels du Baylor College of Medicine, Dr. Karl Kieburtz de l'Université de Rochester School of Medicine, et Dr. Stephen Moss de l'Université de Tufts. L'événement sera disponible par webdiffusion, et les participants sur place peuvent s'inscrire auprès des Relations investisseurs d'Ovid.
Ovid Therapeutics (Nasdaq: OVID) hat eine Investorenveranstaltung namens KCC2 Download Day angekündigt, die am 13. November 2024 von 9:30 bis 11:30 Uhr ET in ihrem Hauptsitz in New York stattfinden wird. Die Veranstaltung wird sich auf ihr Portfolio an direkten Kaliumchlorid-Cotransporter 2 (KCC2) Aktivatoren konzentrieren, einschließlich Updates zu OV350, ihrem Hauptprogramm.
Drei hervorragende Redner werden präsentieren: Dr. Jeffrey Noebels vom Baylor College of Medicine, Dr. Karl Kieburtz von der University of Rochester School of Medicine und Dr. Stephen Moss von der Tufts University. Die Veranstaltung wird auch als Webcast verfügbar sein, und persönliche Teilnehmer können sich über die Investor Relations von Ovid anmelden.
- None.
- None.
KCC2 Download Day on Wednesday, November 13, 2024
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that it will host an investor event focused on its portfolio of direct potassium chloride co-transporter 2 (KCC2) activators on Wednesday, November 13, 2024. The event will take place at Ovid’s headquarters in New York’s Hudson Yards from 9:30 to 11:30 am ET and will be webcast simultaneously.
The session will focus on the biological relevance and broad potential therapeutic opportunity associated with Ovid’s KCC2 portfolio. Company management will provide updates on the portfolio’s programs, including the first in the franchise, OV350. Recognized thought leaders in neurology and neuropharmacology will present, including:
- Jeffrey Noebels, M.D., Ph.D. - Cullen Trust for Health Care Endowed Chair in Neurogenetics and Professor of Neurology, Neuroscience, and Molecular and Human Genetics at Baylor College of Medicine, and Director of The Blue Bird Circle Developmental Neurogenetics Laboratory
- Karl Kieburtz, M.D., M.P.H. - Professor of Neurology, University of Rochester School of Medicine, and Managing Principal of Clintrex Research LLC
- Stephen Moss, Ph.D. - Director of the Moss Labs for Neuropharmacology within Tufts University Neuroscience Department and Professor of Molecular Pharmacology, Department of Neuroscience, Physiology, and Pharmacology, University College, London
Interest in Attending
To attend in person, contact Ovid Investor Relations at IR@ovidrx.com for registration. Breakfast and lunch will be provided.
A live webcast of the presentation can be accessed through the Events & Presentations section of Ovid's website at https://investors.ovidrx.com.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company that is dedicated to improving the lives of people affected by rare epilepsies and brain conditions. Ovid is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. Ovid is developing: OV888/GV101 capsule, a potent and highly selective rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, for the potential treatment of cerebral cavernous malformations and other rare central nervous system diseases; OV329, a GABA-AT inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the potassium-chloride co-transporter 2 (KCC2), for the potential treatment of epilepsies, neurodegenerative and other psychiatric conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com.
Forward- Looking Statements
This press release includes certain disclosures by Ovid that contain “forward-looking statements” including, without limitation: the therapeutic potential of any of Ovid’s KCC portfolio, including OV350; the potential therapeutic opportunity of OV888/GV101 capsule, and OV329; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plan,” “potentially,” and “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, the risk that results of preclinical studies or earlier clinical trials are not necessarily predictive of future results, our drug candidates may not have favorable results in planned or future preclinical studies or clinical trials, or may not receive regulatory approval. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption “Risk Factors” in Ovid’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 13, 2024, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Investor Relations:
Garret Bonney
gbonney@ovidrx.com
Media:
Raquel Cabo
rcabo@ovidrx.com
FAQ
When is Ovid Therapeutics hosting their KCC2 Download Day investor event?
What is the main focus of Ovid Therapeutics' (OVID) November 2024 investor event?
Who are the keynote speakers at Ovid Therapeutics' KCC2 Download Day?